- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01184885
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
A Pilot Study of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) With Sirolimus for the Treatment of Adult Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this trial is to characterize the feasibility, safety and tolerability of therapy with Hyper-CVAD and Rapamycin in adults with ALL and other aggressive lymphoid malignancies.
This study will evaluate the effectiveness of Rapamycin given in combination with Hyper-CVAD during A treatment cycles, and Methotrexate and Cytarabine in B treatment cycles. Both cycles will also contain the drug Rituximab if the patient has a B cell type of leukemia or lymphoma.
This combination of drugs are being studied to determine whether or not these drugs will have an effect in treating this disease.
Current therapeutic regimens for induction of remission in ALL are broadly similar. There is no single best regimen for induction therapy. The hyper-CVAD regimen is of particular interest because it does not include asparaginase as part of the therapeutic regimen and the results of induction are similar to other published regimens.
The HyperCVAD regimen with or without rituximab is also an accepted induction regimen for lymphoblastic lymphoma, Burkitt and Burkitt like lymphoma, Mantle Cell Lymphoma, and ALL in the elderly. The regimen has also been used as a salvage regimen in patients with the above diagnoses who have relapsed after another induction regimen.
This trial will add a novel agent, an mTOR inhibitor (MTI), rapamycin, to act synergistically with the HyperCVAD regimen. This is a pilot study, assessing the feasibility, safety and toxicity of this regimen, with an ultimate goal to perform a phase II study to evaluate response rates and survival.
This is a pilot study of the Hyper-CVAD regimen with Rapamycin for the treatment of adults with acute lymphoblastic leukemia or other aggressive lymphoid malignancies. The standard Hyper-CVAD regimen will be used, with the addition of the investigational agent, Rapamycin. Hyper-CVAD alone is one of the current standard induction and salvage regimens used to treat ALL and other aggressive lymphoid malignancies.
Subjects included will have either de novo, relapsed, or refractory ALL or another aggressive lymphoid malignancy.
Chemotherapy will consist of 4 'A' cycles alternating with 4 'B' cycles, every 21 days, or as count recovery allows (at least 14 days apart) as follows: 1A; 1B; 2A; 2B, 3A; 3B; 4A; 4B. This is dependent on white blood cell count recovery.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have a diagnosis of one of the following lymphoid malignancies (new or relapsed):
- Acute Lymphoblastic Leukemia (B and T cell, Philadelphia Chromosome Negative)
- Burkitt Lymphoma
- Burkitt - type Lymphoma
- Lymphoblastic Lymphoma
- Mantle Cell Lymphoma
- Adult T cell Leukemia/ lymphoma
- Patients must be >18 years old
- Patients must have an ECOG performance status of 0 or 1(see attachment 1).
- Patients must have a life expectancy of at least 4 weeks.
- Patients must be able to consume oral medication.
- Patients must have completed any radiotherapy four weeks prior to study entry, 0-2 weeks for local palliative XRT (small port).
- Patients must have recovered from the toxic effects of any prior chemotherapy to < grade 2 (except alopecia).
- Required initial laboratory values: Creatinine < or = 2.0mg/dL; total or direct bilirubin < or = 1.5mg/dL (if not due to the leukemia or lymphoma itself); SGPT(ALT) < or = 3xULN; glucose <200 mg/dL, negative pregnancy test for women with child-bearing potential.
- Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
- Patients may have had a prior stem cell transplant (autologous or allogeneic), however they may not have active GvHD, nor be on any immunosuppression
Exclusion Criteria:
- Patients must not be receiving any chemotherapy agents (except Hydroxyurea)
- Intrathecal ARA-C and intrathecal methotrexate are permissible (as they are not systemic and only isolated to the central nervous system).
- Patients must not be receiving growth factors, except for erythropoietin.
- Patients with a current second malignancy requiring systemic therapy, other than non-melanoma skin cancers, are not eligible.
- Patients with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia are not eligible.
Patients taking any of the following drugs while on-study are not eligible:
- Carbamazepine (e.g. Tegretol)
- Rifabutin (e.g. Mycobutin)
- Rifampin (e.g. Rifadin)
- Rifapentine (e.g. Priftin)
- St. John's Wort- may decrease the effects of sirolimus by decreasing the amount of sirolimus in the body
- Clarithromycin (e.g. Biaxin)
- Cyclosporin e.g. (Neorla or Sandimmune)
- Diltiazem (e.g. Cardizem)
- Erythromycin (e.g. Akne-Mycin, Ery-Tab)
- Itraconazole (e.g. Sporanox)
- Ketoconazole (e.g. Nizoral)
- Telithromycin (e.g. Ketek)
- Verapamil (e.g. Calan SR, Isoptin, Verelan)
- Voriconazole (e.g. VFEND) - May increase the effects of sirolimus by increasing the amount of this medicine in the body. [Cannot be taken within 72 hours prior to or subsequent to receiving rapamycin, but may be taken prior to or after the above time period]
- Tacrolimus (e.g. Prograf) - May cause liver transplant rejection or serious side effects in patients on sirolimus.
- Patients with known HIV positivity or AIDS-related illness are not eligible.
- Patients with other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study are ineligible.
- Patients must not have evidence of cerebellar dysfunction or prior history of cerebellar dysfunction with Ara-C administration.
- Patients must not have received any investigational agents within 30 days of study entry.
- Patients must not be pregnant or breastfeeding. Pregnancy tests must be obtained for all females of child-bearing potential. Pregnant or lactating patients are ineligible for this study due to the unknown human fetal or teratogenic toxicities of rapamycin. Males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive method.
- Patients who have uncontrolled infection are not eligible. Patients must have any active infections under control. Fungal disease must be stable for at least 2 weeks before study entry. Patients with bacteremia must have documented negative blood cultures prior to study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hyper-CVAD and Sirolimus
|
Other Names:
Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Count Recovery That Allows for Starting a Phase II Study to Evaluate Response Rates and Survival
Time Frame: 18 months
|
This will be assessed by evaluating the tolerability of this regimen compared to historical controls who received Hyper-CVAD or Hyper-CVAD/ Rituximab regimens. The treatment will be designated feasible for an individual subject if in 80% of chemotherapy cycles the subject has count recovery that allows for starting the subsequent cycle by Day 28. Count recovery is defined as ANC (absolute neutrophil count) of > 0.5 x 10^9/L and platelet count > 50 x 10^9/L. Hyper-CVAD/Rapamycin will be deemed acceptable if it is feasible to administer in 80% or more of subjects. |
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Induction Mortality
Time Frame: 18 months
|
Induction mortality.
Hyper-CVAD/ Rapamycin will be considered acceptable if induction mortality does not exceed 31% in patients older than 60, or 15% in those younger than 60
|
18 months
|
Complete Response
Time Frame: Every 21 days or as count recovery allows (at least 14 days apart) up to 24 weeks
|
To describe response rates to hyper-CVAD and sirolimus in adults with ALL and other aggressive lymphoid malignancies. Bone marrow (<5% blasts) with adequate bone marrow cellularity, no evidence of circulating blasts or extramedullary disease and normalization of peripheral blood counts except for platelets (neutrophil count =1,000/µL). |
Every 21 days or as count recovery allows (at least 14 days apart) up to 24 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- DNA Virus Infections
- Tumor Virus Infections
- Epstein-Barr Virus Infections
- Herpesviridae Infections
- Lymphoma, B-Cell
- Neoplasms
- Lymphoma
- Leukemia
- Burkitt Lymphoma
- Lymphoma, Mantle-Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Leukemia, T-Cell
- Leukemia-Lymphoma, Adult T-Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Cyclophosphamide
- Sirolimus
Other Study ID Numbers
- 09G.474
- 2009-35 (Other Identifier: AP HM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burkitt Lymphoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Burkitt Lymphoma | AIDS-Related Burkitt Lymphoma | Atypical Burkitt/Burkitt-Like Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2... and other conditionsUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.Active, not recruitingDiffuse Large B-Cell Lymphoma | Plasmablastic Lymphoma | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Adult Burkitt Lymphoma | MYC Gene MutationUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Burkitt Lymphoma | Childhood Lymphoblastic LymphomaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's HospitalTerminatedBurkitt Lymphoma | Non-Hodgkins Lymphoma | Atypical Burkitt LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Adult Lymphoblastic Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent... and other conditionsUnited States
-
PETHEMA FoundationGrupo Español de Linfomas y Transplante Autólogo de Médula ÓseaRecruitingMature B-Cell Leukemia Burkitt Type | Burkitt Lymphoma (BL) | Unclassifiable Lymphoma Between DCBL and BLSpain
-
Hospices Civils de LyonThe Lymphoma Academic Research OrganisationRecruitingMantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Diffuse Large B Lymphoma (DLBCL) | Marginal Zone Lymphoma (MZL) | T-cell Lymphoma (T-NHL) | Hodgkin's Lymphoma (HL) | Burkitt Lymphoma (BL))France
-
National Cancer Institute (NCI)CompletedRecurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Adult Diffuse Large Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Burkitt Lymphoma | Refractory Burkitt LymphomaUnited States
Clinical Trials on Hyper-CVAD
-
University of Wisconsin, MadisonCompleted
-
M.D. Anderson Cancer CenterNot yet recruitingB-cell Acute Lymphocytic Leukemia | Relapsed/RefractoryUnited States
-
Peking University Cancer Hospital & InstituteRecruiting
-
Eye-yon MedicalCompletedCorneal EdemaIsrael
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownEpithelial Ovarian Carcinoma | Figo Stage IIICFrance
-
University of Colorado, DenverChildren's Hospital ColoradoRecruitingCentral Venous Catheter Related Bloodstream Infection | Central Venous Catheter Exit Site InfectionUnited States
-
University of CambridgeUniversity of ManchesterNot yet recruitingEndoscopyUnited Kingdom
-
Rigshospitalet, DenmarkActive, not recruitingSubarachnoid Hemorrhage, AneurysmalDenmark
-
H. Lee Moffitt Cancer Center and Research InstituteServierRecruitingAcute Lymphoblastic LeukemiaUnited States
-
InnoRa GmbHTerminatedLesions in the Superficial Femoral Artery and/or Popliteal Artery Pars I/IIGermany